ArticleAmerican journal of translational research2025
Montelukast Sodium combined with Erythromycin Cyclocarbonate shows promoting effects on Mycoplasma pneumoniae infection in children.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the efficacy of Montelukast Sodium in combination with Erythromycin Cyclocarbonate for the treatment of children with Mycoplasma Pneumoniae infection, as well as their effects on the improvements of lung function, serum stress indicators, and antioxidant capacity indicators.
methodsA retrospective analysis was conducted on 188 children with Mycoplasma Pneumoniae infection treated in Dujiangyan Shoujia Hospital from April 2023 to April 2024. The 188 children were divided into the research group (n=94) and the control group (n=94) according the treatment they received, with children in the research group receiving a combination of Erythromycin Cyclocarbonate and Montelukast Sodium tablets, while those in the control group receiving Erythromycin Cyclocarbonate only. The therapeutic efficacy, pulmonary function, symptom alleviation time, serum stress indicator levels, antioxidant capacity indicators, and serum IgA and IgM levels of participants were statistically analyzed and compared between the two groups.
resultsIn comparison to the control group, the research group demonstrated better clinical efficacy, shorter time for the clinical symptoms to disappear, significant improvement in pulmonary function indicators, markedly decreased serum stress indicators (P < 0.05), significantly increased serum IgA and IgM levels (P < 0.05), as well as notably improved antioxidant capacity indicators (P < 0.05).
conclusionMontelukast Sodium in combination with Erythromycin Cyclocarbonate treatment regimen increases the efficacy in treating Mycoplasma Pneumoniae infection in children compared to the use of Erythromycin Cyclocarbonate alone. This combination therapy can alleviate clinical symptoms faster, improve pulmonary function, reduce serum stress indicators, reduce the occurrence of adverse events, and enhance immune function in children with Mycoplasma Pneumoniae infection post treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.